Cargando…

In vitro additive effects of dalbavancin and rifampicin against biofilm of Staphylococcus aureus

Dalbavancin is a novel glycopeptide antibiotic approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). It is characterized by a potent activity against numerous Gram-positive pathogens, a long elimination half-life and a favorable safety profile. Most recently, it...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jacob, Benjamin, Makarewicz, Oliwia, Hartung, Anita, Brodt, Steffen, Roehner, Eric, Matziolis, Georg
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648795/ https://www.ncbi.nlm.nih.gov/pubmed/34873186 http://dx.doi.org/10.1038/s41598-021-02709-x

Ejemplares similares

Tedizolid-Rifampicin Combination Prevents Rifampicin-Resistance on in vitro Model of Staphylococcus aureus Mature Biofilm
por: Gidari, Anna, et al.
Publicado: (2020)

Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE)
por: Knafl, D., et al.
Publicado: (2016)

Dalbavancin for Staphylococcus aureus Bacteremia: Are We There Yet?
por: Mahatanan, Rattanaporn, et al.
Publicado: (2023)

1268. Dalbavancin for the Treatment of Infections due to Staphylococcus aureus
por: Streifel, Amber C, et al.
Publicado: (2020)

In Vitro Activity of Dalbavancin against Refractory Multidrug-Resistant (MDR) Staphylococcus aureus Isolates
por: Bongiorno, Dafne, et al.
Publicado: (2020)

Dalbavancin Use for the Treatment of Methicillin-resistant Staphylococcus aureus Pneumonia
por: Barber, Katie E., et al.
Publicado: (2017)

Fitness of Spontaneous Rifampicin-Resistant Staphylococcus aureus Isolates in a Biofilm Environment
por: Maudsdotter, Lisa, et al.
Publicado: (2019)

Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials
por: Gonzalez, Pedro L., et al.
Publicado: (2021)

Dalbavancin Boosts the Ability of Neutrophils to Fight Methicillin-Resistant Staphylococcus aureus
por: Scutera, Sara, et al.
Publicado: (2023)

In Vitro Activity of Rifampicin Combined with Daptomycin or Tigecycline on Staphylococcus haemolyticus Biofilms
por: Szczuka, Ewa, et al.
Publicado: (2015)

Titanium-Tethered Vancomycin Prevents Resistance to Rifampicin in Staphylococcus aureus in vitro
por: Rottman, Martin, et al.
Publicado: (2012)

Comparison of Sequential Dalbavancin With Standard-of-Care Treatment for Staphylococcus aureus Bloodstream Infections
por: Molina, Kyle C, et al.
Publicado: (2022)

A blue fluorescent labeling technique utilizing micro- and nanoparticles for tracking in LIVE/DEAD(®) stained pathogenic biofilms of Staphylococcus aureus and Burkholderia cepacia
por: Klinger-Strobel, Mareike, et al.
Publicado: (2016)

MBEC Versus MBIC: the Lack of Differentiation between Biofilm Reducing and Inhibitory Effects as a Current Problem in Biofilm Methodology
por: Thieme, Lara, et al.
Publicado: (2019)

Adaptation of the Start-Growth-Time Method for High-Throughput Biofilm Quantification
por: Thieme, Lara, et al.
Publicado: (2021)

Plain radiographic indices are reliable indicators for quantitative bone mineral density in male and female patients before total hip arthroplasty
por: Rohe, Sebastian, et al.
Publicado: (2023)

Role of Extracellular DNA in Dalbavancin Activity against Methicillin-Resistant Staphylococcus aureus (MRSA) Biofilms in Patients with Skin and Soft Tissue Infections
por: Sivori, Francesca, et al.
Publicado: (2022)

Surface charge modulation of rifampicin-loaded PLA nanoparticles to improve antibiotic delivery in Staphylococcus aureus biofilms
por: Da Costa, David, et al.
Publicado: (2021)

Dalbavancin as Secondary Therapy for Serious Staphylococcus aureus Infections in a Vulnerable Patient Population
por: Bryson-Cahn, Chloe, et al.
Publicado: (2019)

2255. The Use of Dalbavancin for Staphylococcus aureus Bacteremia in Persons Who Inject Drugs (PWID)
por: Van Hise, Nicholas W, et al.
Publicado: (2019)

Dalbavancin is thermally stable at clinically relevant temperatures against methicillin-sensitive Staphylococcus Aureus
por: Hoyt, Aaron K., et al.
Publicado: (2023)

A simple method of measuring the wear of explanted acetabular component inserts
por: Krakow, L., et al.
Publicado: (2017)

Rifampicin-Manuka Honey Combinations Are Superior to Other Antibiotic-Manuka Honey Combinations in Eradicating Staphylococcus aureus Biofilms
por: Liu, Michael Y., et al.
Publicado: (2018)

Dalbavancin for treatment of implant-related methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model
por: Kussmann, Manuel, et al.
Publicado: (2018)

Dalbavancin treatment of methicillin-susceptible Staphylococcus aureus pyomyositis with torpid evolution: a case report
por: Otero, Judith Álvarez, et al.
Publicado: (2019)

Intraarticular vancomycin powder is effective in preventing infections following total hip and knee arthroplasty
por: Matziolis, Georg, et al.
Publicado: (2020)

C-reactive protein during the first 6 postoperative days after total hip arthroplasty cannot predict early periprosthetic infection
por: Rohe, Sebastian, et al.
Publicado: (2022)

Topical vancomycin powder does not affect patella cartilage degeneration in primary total knee arthroplasty and conversion rate for secondary patella resurfacing
por: Jacob, Benjamin, et al.
Publicado: (2022)

Evolution of resistance mechanisms and biological characteristics of rifampicin-resistant Staphylococcus aureus strains selected in vitro
por: Wang, Chong, et al.
Publicado: (2019)

Evolution of Antibiotic Tolerance During Oxacillin, Daptomycin and Dalbavancin Therapy Results in Breakthrough Staphylococcus aureus Bacteremias
por: Berti, Andrew, et al.
Publicado: (2017)

Sub-Inhibitory Concentrations of Rifampicin Strongly Stimulated Biofilm Production in S. aureus
por: Lima-e-Silva, Agostinho Alves, et al.
Publicado: (2017)

Treatment of Staphylococcus aureus skin infection in vivo using rifampicin loaded lipid nanoparticles
por: Walduck, Anna, et al.
Publicado: (2020)

In Vitro Activities of Ceftobiprole, Dalbavancin, Tedizolid and Comparators against Clinical Isolates of Methicillin-Resistant Staphylococcus aureus Associated with Skin and Soft Tissue Infections
por: Maraki, Sofia, et al.
Publicado: (2023)

1829. Dalbavancin versus standard of care as directed therapy for Staphylococcus aureus bacteremia in patients unable to receive OPAT
por: Frazier, J, et al.
Publicado: (2022)

Novel dalbavancin-PLLA implant coating prevents hematogenous Staphylococcus aureus infection in a minimally invasive mouse tail vein model
por: Kloss, Marlen, et al.
Publicado: (2022)

In Vitro Efficacy of Dalbavancin as a Long-Acting Anti-Biofilm Agent Loaded in Bone Cement
por: Sánchez-Somolinos, Mar, et al.
Publicado: (2023)

Dalbavancin
por: Barberán, José, et al.
Publicado: (2021)

Effect of Dalbavancin on Staphylococcal Biofilms When Administered Alone or in Combination With Biofilm-Detaching Compounds
por: Žiemytė, Miglë, et al.
Publicado: (2020)

Synergism between Medihoney and Rifampicin against Methicillin-Resistant Staphylococcus aureus (MRSA)
por: Müller, Patrick, et al.
Publicado: (2013)

Genetic Screen Reveals the Role of Purine Metabolism in Staphylococcus aureus Persistence to Rifampicin
por: Yee, Rebecca, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_b4o3qqfav5d87enlnb2fc2d2ei